New Zealand Blackcurrant and Recovery in Elite Taekwondo (NZBC-TAE)
Effects of New Zealand Blackcurrant Extract Supplementation on Muscle Damage, Oxidative Stress, and Inflammatory Markers Following High-Intensity Training in Elite Taekwondo Athletes
This randomized, double-blind, placebo-controlled trial evaluated the effects of short-term supplementation with anthocyanin-rich New Zealand blackcurrant (NZBC) extract on exercise-induced muscle damage, oxidative stress, antioxidant status, inflammatory responses, and perceived muscle soreness in elite male taekwondo athletes.
Thirty national-level male taekwondo athletes were enrolled and randomly assigned in a 1:1 ratio to receive either NZBC extract (CurraNZ®, UK; 600 mg/day providing approximately 210 mg anthocyanins) or a matched placebo for 7 days. Blood samples and muscle soreness ratings were collected at baseline, immediately after exercise, 24 hours after exercise, and after 7 days.
The primary outcome was plasma creatine kinase (CK). Secondary outcomes included reactive oxygen species (ROS), total antioxidant capacity (TOAC), protein carbonyls, inflammatory cytokines (IL-6, TNF-α, and IL-10), and perceived muscle soreness assessed using a visual analog scale (VAS).
The study was approved by the Biruni University Clinical Research Ethics Committee (No. 2015-KAEK-80-23-33; December 22, 2023). Written informed consent was obtained from all participants.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
High-intensity, impact-based sports such as taekwondo involve substantial mechanical and metabolic demands that may contribute to exercise-induced muscle damage, oxidative stress, inflammatory responses, and delayed recovery. Nutritional strategies capable of modulating these physiological responses may therefore be relevant for athletes exposed to repeated high-intensity training.
New Zealand blackcurrant (Ribes nigrum L.) is rich in anthocyanins and other polyphenolic compounds with antioxidant and anti-inflammatory properties. Previous studies involving endurance and intermittent exercise have investigated the potential effects of blackcurrant supplementation on oxidative stress, vascular responses, exercise performance, and recovery. However, evidence in elite combat-sport athletes remains limited.
The objective of this randomized controlled trial was to determine whether 7 days of standardized NZBC extract supplementation influenced biochemical markers of muscle damage, oxidative stress, antioxidant status, inflammatory cytokines, and perceived muscle soreness following repeated high-intensity training in elite male taekwondo athletes.
It was hypothesized that NZBC supplementation would attenuate exercise-associated elevations in plasma creatine kinase and reactive oxygen species, increase total antioxidant capacity, and modulate inflammatory cytokine responses, including IL-6, TNF-α, and IL-10.
The study used a randomized, double-blind, placebo-controlled, parallel-group design and was conducted at the Atik Ali Sports Club in Istanbul, Türkiye, between December 2023 and June 2024. Thirty elite male taekwondo athletes were enrolled and randomly allocated in a 1:1 ratio to receive either NZBC extract or placebo.
Participants assigned to the intervention group received 600 mg/day of New Zealand blackcurrant extract (CurraNZ®, UK), providing approximately 210 mg of anthocyanins, for 7 consecutive days. Participants assigned to the control group received a visually matched maltodextrin placebo. Randomization, allocation concealment, and blinding procedures were maintained throughout the intervention and until database lock.
Blood samples were collected at baseline, immediately following exercise, 24 hours after exercise, and after 7 days. Biochemical outcomes included plasma creatine kinase, reactive oxygen species, total antioxidant capacity, protein carbonyls, IL-6, IL-10, and TNF-α. Biomarkers were assessed using commercially available laboratory assay kits. Perceived muscle soreness was evaluated using a visual analog scale. Dietary intake and anthropometric characteristics were also assessed.
The primary outcome was the change in plasma creatine kinase. Secondary outcomes included reactive oxygen species, total antioxidant capacity, protein carbonyls, IL-6, IL-10, TNF-α, and perceived muscle soreness.
Statistical analyses were conducted using R version 4.3.1. Data distribution was assessed using the Shapiro-Wilk test, and homogeneity of variance was evaluated using Levene's test. Between-group comparisons were planned using independent-samples t-tests or Mann-Whitney U tests, as appropriate. Longitudinal changes were evaluated using repeated-measures analysis of variance, including group, time, and group × time interaction effects. Greenhouse-Geisser corrections were applied where assumptions of sphericity were not met. Sensitivity analyses were conducted using linear mixed-effects models. Statistical significance was defined as a two-tailed alpha level of 0.05.
The study was approved by the Biruni University Clinical Research Ethics Committee (No. 2015-KAEK-80-23-33; December 22, 2023). All participants provided written informed consent before participation.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Tuzla
-
Istanbul, Tuzla, Tyrkiet (Türkiye), 34000
- Okan university
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Male national-level taekwondo athletes actively training and competing
- Age between 18 and 35 years
- Free from any chronic disease, metabolic disorder, or recent musculoskeletal injury
- Not using antioxidant, anti-inflammatory, or ergogenic supplements within the last 4 weeks
- Willing to maintain regular diet and training schedule during the study period
- Provided written informed consent
Exclusion Criteria:
- Female athletes
- Presence of chronic illness, injury, or infection
- Use of antioxidant or anti-inflammatory supplements in the 4 weeks prior to enrollment
- Dietary habits incompatible with the intervention (e.g., high anthocyanin intake from other sources)
- Failure to complete all study visits or provide required blood samples
- Withdrawal of consent at any time
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Støttende pleje
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: New Zealand Blackcurrant Extract (NZBC)
Participants received New Zealand blackcurrant extract capsules (CurraNZ®, Healthspan Elite, UK) for 7 days. The daily dose was 600 mg (two 300 mg capsules, morning and evening), providing approximately 210 mg anthocyanins per day. |
Standardized anthocyanin-rich blackcurrant extract administered orally at 600 mg/day (two 300 mg capsules) for 7 consecutive days. Each capsule contained natural polyphenolic compounds standardized to ~35% anthocyanins. |
|
Placebo komparator: Placebo
Participants received placebo capsules identical in appearance to the NZBC capsules, containing maltodextrin. The placebo was administered orally twice daily for 7 days. |
Two identical capsules containing maltodextrin, taken daily for 7 days (morning and evening), matching the NZBC supplementation schedule. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in plasma Creatine Kinase (CK) concentration
Tidsramme: Baseline, immediately post-exercise, 24 hours, and 7 days after training
|
Plasma creatine kinase (CK) activity measured via ELISA assay as a biomarker of exercise-induced muscle damage. The outcome represents the change in CK levels from baseline to 24 h and 7 d after repeated high-intensity training sessions. |
Baseline, immediately post-exercise, 24 hours, and 7 days after training
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Reactive Oxygen Species (ROS) levels
Tidsramme: Baseline, immediately post-exercise, 24 hours, and 7 days
|
ROS concentrations measured by ELISA to assess oxidative stress response following high-intensity training. |
Baseline, immediately post-exercise, 24 hours, and 7 days
|
|
Change in Total Antioxidant Capacity (TOAC)
Tidsramme: Baseline, 24 hours, and 7 days
|
Total antioxidant capacity determined spectrophotometrically using commercial assay kits (Sunredbio, China). Reflects systemic antioxidant defense. |
Baseline, 24 hours, and 7 days
|
|
Change in Inflammatory Cytokines (IL-6, TNF-α, IL-10)
Tidsramme: Baseline, 24 hours, and 7 days
|
Serum IL-6, TNF-α, and IL-10 quantified by ELISA to evaluate systemic inflammatory and anti-inflammatory responses to exercise and supplementation. |
Baseline, 24 hours, and 7 days
|
|
Perceived Muscle Soreness (Visual Analog Scale, VAS)
Tidsramme: Baseline, 12 hours, 24 hours after each training day, and 7 days
|
Subjective muscle soreness assessed using a 10-cm visual analog scale (VAS), where 0 = no soreness and 10 = extreme soreness. |
Baseline, 12 hours, 24 hours after each training day, and 7 days
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- Hacettepe1234
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Individual participant data (IPD) that underlie the results reported in this article (deidentified participant data, including baseline characteristics and outcome measures) will be made available upon reasonable request to qualified researchers.
Data will be available after publication of the main results for a period of 3 years.
Requests should be directed to the corresponding author (Assoc. Prof. Sedat Arslan, Bandirma Onyedi Eylul University; email: sarslan@bandirma.edu.tr).
No identifying participant information will be shared. Supporting documents such as the study protocol, statistical analysis plan, and informed consent form will also be provided upon request.
IPD-delingstidsramme
Deidentified IPD and supporting documents will be available beginning 1 month after publication of the primary results and for 36 months thereafter. If publication is delayed, access will begin 12 months after database lock. Extensions may be granted upon justified request.
IPD-delingsadgangskriterier
Qualified researchers with a methodologically sound proposal may request access by emailing the corresponding author (Assoc. Prof. Sedat Arslan; sarslan@bandirma.edu.tr). Requests must include a brief protocol, objectives, analysis plan, and IRB/ethics determination (if applicable). A data use agreement is required. Only deidentified IPD (baseline characteristics and prespecified outcomes) and documentation (protocol, SAP, ICF templates, analytic code) will be shared. Data will be provided via a secure institutional repository link; re-identification and commercial use are prohibited.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .